Health
What WHO Malaria-Free Certification Requires
A country must prove beyond reasonable doubt that local transmission of all human malaria parasites stopped nationwide for at least three consecutive years and that it can prevent transmission from returning.
Lipfendra Approval: The First Oral PCSK9 Inhibitor
FDA approved once-daily enlicitide, sold as Lipfendra, as an addition to diet and exercise for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
What Is Journavx? The First-in-Class Non-Opioid Pain Drug
FDA approved Journavx, or suzetrigine, in January 2025 for moderate to severe acute pain in adults, creating a non-opioid analgesic class that targets peripheral sodium-channel pain signaling.
Isembyld Approval: First Therapy Targeting Muscle Loss in SMA
FDA approved Isembyld, or apitegromab-mstn, for people age two and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Leqembi At-Home Starting Dose: What FDA Approved in 2026
The FDA approved a subcutaneous starting regimen for Leqembi IQLIK that can be administered at home by a patient or caregiver, while retaining important screening and safety requirements.
Rasonque Approval: First-in-Class RAS Therapy for Pancreatic Cancer
FDA approved daraxonrasib, sold as Rasonque, for certain adults with metastatic pancreatic adenocarcinoma after prior treatment or when multiagent therapy is unsuitable.
Alyftrek Ingredients and How the Triple Therapy Works
Alyftrek combines vanzacaftor and tezacaftor, which help more CFTR protein reach the cell surface, with deutivacaftor, which helps responsive CFTR channels stay open.
How Egypt Became Malaria-Free
WHO certified Egypt malaria-free in October 2024 after the country demonstrated at least three consecutive years without indigenous transmission and the capacity to prevent its return.
Notable FDA Drug Approvals in 2026: What “First” Really Means
FDA's 2026 notable-approval list included first-in-class mechanisms, first oral versions, new routes and new age groups, each describing a different kind of regulatory milestone.
Who Can Take Alyftrek for Cystic Fibrosis?
The original FDA indication covered people age six and older with cystic fibrosis who had at least one F508del mutation or another CFTR mutation shown to respond to the medicine.